5%卡泊三醇乳膏外用治疗光化性角化病的初步开放性研究。
Topical treatment of actinic keratoses with potassium dobesilate 5% cream. a preliminary open-label study.
机构信息
Servicio de Histologia, IRYCIS, Hospital Ramon y Cajal, Ctra. de Colmenar km. 9.100, 28034-Madrid, Spain.
出版信息
Eur J Med Res. 2011 Feb 24;16(2):67-70. doi: 10.1186/2047-783x-16-2-67.
BACKGROUND
Fibroblast growth factor (FGF) is involved in skin tumorigenesis: it promotes cell viability, induces angiogenesis and stimulates invasiveness. Dobesilate is a drug that blocks the activity of FGF. The primary objective was to evaluate the efficacy and tolerability of potassium dobesilate 5% cream in the treatment of actinic keratoses.
METHODS
Potassium dobesilate 5% cream was applied twice daily for 16 weeks to actinic keratosis lesions in 30 patients. The lesions were evaluated clinically at an initial baseline visit, at intermediate visits, and at 16 weeks of treatment. -
RESULTS
The use of potassium dobesilate 5% cream for 16 weeks induced complete regression in 70% of evaluated actinic keratoses, corresponding to grade I, II and III clinical variants, and a partial response (at least 75% reduction of lesions) in 20% of the cases.
CONCLUSION
Our preliminary trial shows that potassium dobesilate exerts anti-tumorigenic effects and may play a useful role in the chemoprevention of skin cancers.
背景
成纤维细胞生长因子（FGF）参与皮肤肿瘤的发生：它促进细胞活力，诱导血管生成并刺激侵袭性。多贝斯是一种能阻断 FGF 活性的药物。主要目的是评估 5%多贝斯钾乳膏治疗光化性角化病的疗效和耐受性。
方法
30 名患者的光化性角化病病变处每日两次涂抹 5%多贝斯钾乳膏，持续 16 周。在初始基线访视、中间访视和治疗 16 周时对病变进行临床评估。
结果
使用 5%多贝斯钾乳膏治疗 16 周后，70%的评估光化性角化病完全消退，对应于 I、II 和 III 级临床变异，20%的病例有部分反应（病变至少减少 75%）。
结论
我们的初步试验表明，多贝斯具有抗肿瘤作用，可能在皮肤癌的化学预防中发挥有用作用。
Zotero 插件